Cyclerion reports FY2021 net loss $51.6M; MELAS topline data expected Q2 2022

Cyclerion Therapeutics, Inc.

2022-FY EPS reported -$1.32 revenue$3,942,000

Net loss $51.6M for FY2021 vs $77.8M in FY2020; cash $54M at Dec 31, 2021.
R&D expense $37.6M (down from $56.4M); G&A $20.6M (down from $28.8M).
Phase 2a MELAS trial enrollment closed; topline data expected in Q2 2022.
Phase 1b CIAS trial enrollment ongoing; topline expected H2 2022; Phase 2a ADv trial initiated.
Bruce Kinon appointed VP Clinical Development; collaboration with Ariana Pharma for AI biomarker discovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.